Asset

Amoxicillin

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Revenue

No revenue reported in loaded filings.

Clinical trials (5)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT04753437phase1completed2021-04-062021-09-27TakedaA Study of Vonoprazan in Adults With Helicobacter Pylori
NCT04198363phase3completed2020-04-302021-11-01TakedaA Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection
NCT01442688phase1completed2011-10-072011-11-20ShireAmoxicillin Drug Interaction Study With MMX® Mesalazine/Mesalamine
NCT01505127phase3completed2012-01-012013-06-01TakedaEfficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori
NCT02892409phase1completed2016-09-052017-04-17TakedaTAK-438 Bismuth Drug Interaction Study

FDA applications (1)

ApplicationTypeApplicant
NDA 050757NDATAKEDA PHARMACEUTICALS USA INC

Marketed products (1)

  • PREVPAC (COPACKAGED)